Kailera Therapeutics (KLRA) Financials: Revenue & Earnings

KLRA price $12.99 -0.14 -1.03%

Ticker
KLRA
Price
$12.99
Change
-0.14 -1.03%
Market cap ?
$1.68B
P/E ?
-7.30
Dividend yield ?
0.00%
Beta ?
0.50
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
72
Value
70
Quality
47
Growth
100

Stocklytics score rationale: value 70, quality 47, growth 100.

Financials

2025
0

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1…

Fair value

KLRA fair value Not meaningful. Price $12.99.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Not meaningful

Compare KLRA

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-04—-1.01——
2026-08-12-1.09-0.90——
2026-05-26-3,650.00-0.78——

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-07Nicholson NurBuy220.00K$16.233.57M
2026-08-31Nicholson NurOther0——
2026-07-06Tregoning KathleenBuy175.00K$23.304.08M
2026-06-29Tregoning KathleenOther0——
2026-06-09Renaud Ronald C JRSell38.09K$5.25199.99K
2026-06-09Renaud Ronald C JRBuy38.09K$5.25199.99K
2026-04-20RTW INVESTMENTS, LPBuy500.00K$16.008.00M
2026-04-20RTW INVESTMENTS, LPBuy10.28M——
2026-04-20RTW INVESTMENTS, LPSell8.25M——
2026-04-20RTW INVESTMENTS, LPSell2.03M——
2026-04-20Jiangsu Hengrui Pharmaceuticals Co., Ltd.Buy9.48M——
2026-04-20Jiangsu Hengrui Pharmaceuticals Co., Ltd.Buy2.03M——
2026-04-20Jiangsu Hengrui Pharmaceuticals Co., Ltd.Sell4.97M——
2026-04-20Jiangsu Hengrui Pharmaceuticals Co., Ltd.Sell708.81K——
2026-04-20BAIN CAPITAL INVESTORS LLCBuy8.40M$16.00134.38M
2026-04-20BAIN CAPITAL INVESTORS LLCBuy17.86M——
2026-04-20BAIN CAPITAL INVESTORS LLCSell17.86M——
2026-04-20Koppel AdamBuy1.56M$16.0025.00M
2026-04-20Koppel AdamBuy4.15M——
2026-04-20Koppel AdamBuy16.88M——
2026-04-20Koppel AdamSell16.88M——
2026-04-20Koppel AdamSell4.15M——
2026-04-20Bain Capital Life Sciences Investors, LLCBuy1.56M$16.0025.00M
2026-04-20Bain Capital Life Sciences Investors, LLCBuy4.15M——
2026-04-20Bain Capital Life Sciences Investors, LLCBuy16.88M——
2026-04-20Bain Capital Life Sciences Investors, LLCSell16.88M——
2026-04-20Bain Capital Life Sciences Investors, LLCSell4.15M——
2026-04-20Kaplan Andrew T.Buy8.40M$16.00134.38M
2026-04-20Kaplan Andrew T.Buy17.86M——
2026-04-20Kaplan Andrew T.Sell17.86M——
2026-04-16Koppel AdamBuy38.30K$16.00612.80K
2026-04-16Kaplan Andrew T.Buy38.30K$16.00612.80K
2026-04-16Cloghessy PaulaBuy60.00K$16.00960.00K
2026-04-16Akamine ScottBuy60.00K$16.00960.00K
2026-04-16Renaud Ronald C JRBuy300.00K$16.004.80M
2026-04-16Burgess Paul D.Buy100.00K$16.001.60M
2026-04-16MILLIGAN JOHN FBuy38.30K$16.00612.80K
2026-04-16Coleman Jamie BethBuy75.00K$16.001.20M
2026-04-16MACKAY MARTINBuy38.30K$16.00612.80K
2026-04-16Wasserman Scott M.Buy100.00K$16.001.60M
2026-04-16Hite ChristopherBuy38.30K$16.00612.80K
2026-04-16Clyburn FrankBuy38.30K$16.00612.80K
2026-04-16Pagan Douglas W.Buy100.00K$16.001.60M
2026-04-16Jiangsu Hengrui Pharmaceuticals Co., Ltd.Other0——
2026-04-16Jiangsu Hengrui Pharmaceuticals Co., Ltd.Other9.48M——
2026-04-16Jiangsu Hengrui Pharmaceuticals Co., Ltd.Other2.03M——
2026-04-16Koppel AdamOther16.88M——
2026-04-16Koppel AdamOther4.15M——
2026-04-16BAIN CAPITAL INVESTORS LLCOther17.86M——
2026-04-16Bain Capital Life Sciences Investors, LLCOther16.88M——
2026-04-16Bain Capital Life Sciences Investors, LLCOther4.15M——
2026-04-16Kaplan Andrew T.Other17.86M——
2026-04-16Burgess Paul D.Other191.44K$5.251.01M
2026-04-16Burgess Paul D.Other325.49K$7.242.36M
2026-04-16Wasserman Scott M.Other427.96K$5.252.25M
2026-04-16Wasserman Scott M.Other147.32K$7.241.07M
2026-04-16Pagan Douglas W.Other700.80K$10.097.07M
2026-04-16Coleman Jamie BethOther357.56K$5.401.93M
2026-04-16Coleman Jamie BethOther268.33K$7.241.94M
2026-04-16RTW INVESTMENTS, LPOther8.25M——
2026-04-16RTW INVESTMENTS, LPOther2.03M——
2026-04-16MACKAY MARTINOther170.19K$11.561.97M
2026-04-16Liu YutingOther0——
2026-04-16Hite ChristopherOther81.05K$5.40437.66K
2026-04-16Hite ChristopherOther89.15K$7.24645.42K
2026-04-16Cloghessy PaulaOther86.15K$5.25452.29K
2026-04-16Cloghessy PaulaOther95.35K$5.40514.89K
2026-04-16Cloghessy PaulaOther230.73K$7.241.67M
2026-04-16Renaud Ronald C JROther287.17K$5.251.51M
2026-04-16Renaud Ronald C JROther1.33M$7.249.64M
2026-04-16Clyburn FrankOther170.19K$7.241.23M
2026-04-16Akamine ScottOther143.67K$5.25754.28K
2026-04-16Akamine ScottOther194.00K$7.241.40M
2026-04-16MILLIGAN JOHN FOther285.31K$5.251.50M
2026-04-16MILLIGAN JOHN FOther313.82K$7.242.27M
2026-04-16CANADA PENSION PLAN INVESTMENT BOARDOther5.00M——
2026-04-16Stuart Partners, LLCOther1.43M——

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 102. Ownership 99.40%.

HolderSharesChangeChange %Value
BAIN CAPITAL INVESTORS LLC26.26MNewNew578.41M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC22.58MNewNew497.51M
RTW INVESTMENTS, LP10.78MNewNew237.41M
CANADA PENSION PLAN INVESTMENT BOARD7.30MNewNew160.92M
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC5.17MNewNew113.92M
FMR LLC3.97MNewNew87.48M
BLACKROCK, INC.3.93MNewNew86.55M
PRICE T ROWE ASSOCIATES INC /MD/3.53MNewNew77.86M
CITADEL ADVISORS LLC3.24MNewNew71.39M
ADAGE CAPITAL PARTNERS GP, L.L.C.3.21MNewNew70.68M
WELLINGTON MANAGEMENT GROUP LLP2.92MNewNew64.31M
ROYALTY PHARMA SUB-MANAGER, LLC2.46MNewNew54.09M
SIREN, L.L.C.2.21MNewNew48.78M
VANGUARD CAPITAL MANAGEMENT LLC1.69MNewNew37.32M
VANGUARD PORTFOLIO MANAGEMENT LLC1.65MNewNew36.40M
GEODE CAPITAL MANAGEMENT, LLC1.13MNewNew24.97M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.1.10MNewNew24.23M
FARALLON CAPITAL MANAGEMENT, L.L.C.1.10MNewNew24.23M
TRAILS EDGE CAPITAL PARTNERS, LP984.79KNewNew21.69M
UBS GROUP AG972.68KNewNew21.43M
JUPITER TOPCO LLC970.86KNewNew21.34M
STATE STREET CORP868.16KNewNew19.13M
AMERIPRISE FINANCIAL INC821.33KNewNew18.09M
DEEP TRACK CAPITAL, LP700.00KNewNew15.42M
EVENTIDE ASSET MANAGEMENT, LLC616.72KNewNew13.59M

Earnings and financials

Kailera Therapeutics, Inc. (KLRA) trades at $12.99, with a market cap of $1.68B and a trailing P/E of -7.30. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2025
0

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Kailera Therapeutics (KLRA) Financials: Revenue & Earnings

KLRA$12.99-0.14 -1.03%

$1.68B

Market Cap

-7.30

P/E

—

Forward P/E

72

Score

Price History